The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen
Open accessAbstract
Ivermectin proposes many potentials effects to treat a range of diseases, with its antimicrobial, antiviral, and anti-cancer properties as a wonder drug. It is highly effective against many microorganisms including some viruses. In this comprehensive systematic review, antiviral effects of ivermectin are summarized including in vitro and in vivo studies over the past 50 years. Several studies reported antiviral effects of ivermectin on RNA viruses such as Zika, dengue, yellow fever, West Nile, Hendra, Newcastle, Venezuelan equine encephalitis, chikungunya, Semliki Forest, Sindbis, Avian influenza A, Porcine Reproductive and Respiratory Syndrome, Human immunodeficiency virus type 1, and severe acute respiratory syndrome coronavirus 2. Furthermore, there are some studies showing antiviral effects of ivermectin against DNA viruses such as Equine herpes type 1, BK polyomavirus, pseudorabies, porcine circovirus 2, and bovine herpesvirus 1. Ivermectin plays a role in several biological mechanisms, therefore it could serve as a potential candidate in the treatment of a wide range of viruses including COVID-19 as well as other types of positive-sense single-stranded RNA viruses. In vivo studies of animal models revealed a broad range of antiviral effects of ivermectin, however, clinical trials are necessary to appraise the potential efficacy of ivermectin in clinical setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sohrabi, C., Alsafi, Z., O'Neill, N., Khan, M., Kerwan, A., Al-Jabir, A., Iosifidis, C., & Agha, R. (2020) · International Journal of Surgery · doi:10.1016/j.ijsu.2020.02.034 · Cited by 6,069
Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle
Lu, H., Stratton, C. W., & Tang, Y. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25678 · Cited by 3,504
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104787 · Cited by 2,179
Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor
Ge, X.-Y., Li, J.-L., Yang, X.-L., Chmura, A. A., Zhu, G., Epstein, J. H., Mazet, J. K., Hu, B., Zhang, W., Peng, C., et al. (2013) · Nature · doi:10.1038/nature12711 · Cited by 1,778 · cited 1×
“Although there has been a history of studies on the virus since few years ago [7, 8], as many types of coronaviruses cause simple respiratory tract infections, but SARS-CoV-1 and MERS caused severe respiratory tract illness in infected humans.”
BackgroundWagstaff, K. M., Sivakumaran, H., Heaton, S. M., Harrich, D., & Jans, D. A. (2012) · Biochemical Journal · doi:10.1042/bj20120150 · Cited by 680
A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection
Barrows, N. J., Campos, R. K., Powell, S. T., Prasanth, K. R., Schott-Lerner, G., Soto-Acosta, R., Galarza-Muñoz, G., McGrath, E. L., Urrabaz-Garza, R., Gao, J., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.07.004 · Cited by 497
The Pharmacokinetics and Interactions of Ivermectin in Humans—A Mini-review
González Canga, A., Sahagún Prieto, A. M., Diez Liébana, M. J., Fernández Martínez, N., Sierra Vega, M., & García Vieitez, J. J. (2008) · The AAPS Journal · doi:10.1208/s12248-007-9000-9 · Cited by 419
Mastrangelo, E., Pezzullo, M., De Burghgraeve, T., Kaptein, S., Pastorino, B., Dallmeier, K., de Lamballerie, X., Neyts, J., Hanson, A. M., Frick, D. N., et al. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks147 · Cited by 414
Ivermectin – Old Drug, New Tricks?
Laing, R., Gillan, V., & Devaney, E. (2017) · Trends in Parasitology · doi:10.1016/j.pt.2017.02.004 · Cited by 410
Ivermectin, 'Wonder drug' from Japan: the human use perspective
CRUMP, A., & OMURA, S. (2011) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.87.13 · Cited by 368
Cited by
Bryant, A., Lawrie, T. A., Dowswell, T., Fordham, E. J., Mitchell, S., Hill, S. R., & Tham, T. C. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001402 · Cited by 264
Mody, V., Ho, J., Wills, S., Mawri, A., Lawson, L., Ebert, M. C. C. J. C., Fortin, G. M., Rayalam, S., & Taval, S. (2021) · Communications Biology · doi:10.1038/s42003-020-01577-x · Cited by 257
Hashim, H. A., Maulood, M. F., Rasheed, A. M., Fatak, D. F., Kabah, K. K., & Abdulamir, A. S. (2020) · doi:10.1101/2020.10.26.20219345 · Cited by 98
“This explains how Ivermectin could alleviate symptoms of COVID-19 patients at viral replication phase (the first 7-10 days of infection) as well as the later hyperinflammatory phase [7-10].”
BackgroundInfluentialGheibi (2021) · doi:10.4103/1995-7645.318304 · Cited by 80
Metadata
- Authors
- Heidary, F., & Gharebaghi, R.
- Venue
- The Journal of Antibiotics
- Published
- 2020-06-12
- Volume
- 73
- Issue
- 9
- Pages
- 593-602
- ISSN
- 0021-8820 (ISSN-L)
- 1881-1469
- OpenAlex
- W3035026987
- Cited by
- 435
- References
- 33
- FWCI
- 7.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. https://app.cochat.ai/papers/10.1038/s41429-020-0336-z
- The paper
- Heidary, F., & Gharebaghi, R. (2020). Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. The Journal of Antibiotics. https://doi.org/10.1038/s41429-020-0336-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
